Figure 4 | Scientific Reports

Figure 4

From: Cerebral dopamine neurotrophic factor (CDNF) protects against quinolinic acid-induced toxicity in in vitro and in vivo models of Huntington’s disease

Figure 4

Motor performance in Digigait test. (A) Stride length variability. CDNF-treated group shows the decrease in that parameter during 2 week after treatment. (B) In the relationship between swing and stride phases there was no difference between groups. (C) Ataxia coefficient of the right forelimb (contralateral side) shows a significant decrease in CDNF-treated animals. Values are mean ± SEM. *p = 0.05 vs vehicle, repeated-measures ANOVA, Sidak’s post hoc. N number per group = 7–8. LH left hind limb, RH right hind limb, LF left forelimb, RF right forelimb.

Back to article page